Headlines about AveXis (NASDAQ:AVXS) have trended positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AveXis earned a news sentiment score of 0.28 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.9352643224497 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Novartis International AG – Novartis completes tender offer for all outstanding shares of AveXis, Inc. (romandie.com)
- Notable ETF Inflow Detected – XBI, AVXS, SRPT, ONCE (nasdaq.com)
- Novartis AG: Novartis completes tender offer for all outstanding shares of AveXis, Inc. (twst.com)
- AveXis (AVXS) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
AveXis opened at $217.83 on Friday, MarketBeat reports. AveXis has a twelve month low of $65.54 and a twelve month high of $217.94. The firm has a market cap of $8.02 billion, a price-to-earnings ratio of -29.92 and a beta of 1.55.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of AveXis from a “strong sell” rating to a “hold” rating in a research note on Monday, May 7th. Chardan Capital downgraded shares of AveXis from a “buy” rating to a “neutral” rating in a research note on Friday, April 13th. Jefferies Group downgraded shares of AveXis from a “buy” rating to a “hold” rating in a research note on Wednesday, April 18th. Citigroup downgraded shares of AveXis from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 10th. Finally, Barclays downgraded shares of AveXis from an “overweight” rating to an “equal weight” rating and set a $152.00 price target on the stock. in a research note on Thursday, April 12th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the company’s stock. AveXis has an average rating of “Hold” and a consensus target price of $123.90.
In other AveXis news, VP James J. Litalien sold 5,000 shares of the business’s stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $119.44, for a total transaction of $597,200.00. Following the transaction, the vice president now owns 8,800 shares in the company, valued at $1,051,072. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $126.19, for a total transaction of $224,618.20. The disclosure for this sale can be found here. Insiders have sold 46,780 shares of company stock worth $5,801,268 in the last quarter. Company insiders own 18.60% of the company’s stock.
AveXis Company Profile
AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.